| 36th week of 2008 patent applcation highlights part 37 |
| Patent application number | Title | Published |
|---|
| 20080213216 | Methods of stimulating phagocytosis - The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods. | 2008-09-04 |
| 20080213217 | Enantiomerically pure phosphoindoles as HIV inhibitors - 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds. | 2008-09-04 |
| 20080213218 | METHOD FOR TREATING HEPATITIS C VIRUS INFECTION IN TREATMENT FAILURE PATIENTS - The present invention provides methods for treating individuals having a hepatitis C virus (HCV) infection, which individuals have failed to respond to therapy with an IFN-α other than consensus interferon (CIFN), or who, following cessation of therapy with an IFN-α other than CIFN, have suffered relaspe. The methods generally involve a treatment regimen comprising administering a first dosing regimen of CIFN, followed by a second dosing regimen of CIFN. Ribavirin is administered with at least the second dosing regimen. | 2008-09-04 |
| 20080213219 | Methods for treatment and management of macular degeneration using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione - Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2008-09-04 |
| 20080213220 | Cancer-targeted viral vectors - The present invention relates to viral vectors that are targeted to cancer cells. The viral vectors of the invention are adenoviruses having a PEG-3 promoter driving the expression of the viral genes E1A and E1B. The PEG-3 promoter exhibits increased activity in malignant cells. Adenoviruses of the invention show increased replication in malignant cells, thereby producing a cytopathic effect. The viral vectors of the invention further comprise additional genes of interest, and/or may have altered capsid proteins that may enhance infection of and/or target infection to cancer cells. Additional cell types derived from diseased states in which the PEG-3 promoter is selectively active are also therapeutic targets of the viral vectors of the instant invention including those generating allergic, autoimmune and inflammatory responses. | 2008-09-04 |
| 20080213221 | Compounds and methods to enhance rAAV transduction - Agents and methods to alter rAAV transduction are provided. | 2008-09-04 |
| 20080213222 | Methods And Compositions For Use In Gene Therapy for Treatment of Hemophilia - The invention includes a composition comprising a recombinant adeno-associated viral vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5′ and 3′ untranslated regions and a transcription termination | 2008-09-04 |
| 20080213223 | Systemic viral/ligand gene delivery system and gene therapy - The present invention relates to gene transfer and gene therapy technology. More specifically, the invention provides compositions and methods for targeted virus delivery. The method utilizes a method of mixing the virus, which may be a recombinant virus which will express a protein of interest or a nucleic acid of interest, with a cell-targeting ligand, e.g., transferrin. The virus and ligand are mixed without crosslinkers or agents which would covalently bond the virus and ligand. This simple mixing causes less inactivation than chemically linking the ligand to the virus and therefore results in a more active therapeutic composition than obtained by methods which utilize crosslinking agents. | 2008-09-04 |
| 20080213224 | Immunoglobulin against helicobacter pylori - The present invention relates to materials and methods for prevention, treatment and diagnosing of infections caused by | 2008-09-04 |
| 20080213225 | SULFUR-OXIDIZING PLANT GROWTH PROMOTING RHIZOBACTERIA FOR ENHANCED CANOLA PERFORMANCE - Described herein is the isolation and identification of a number of sulfur oxidizing plant growth promoting rhizobacteria: RAY12, identified as | 2008-09-04 |
| 20080213226 | COMPOSITIONS INCLUDING AMMONIA OXIDIZING BACTERIA AND METHODS OF USING SAME - A preparation and method for treating a subject how had developed or is at risk of developing at least one of high blood pressure, Alzheimer's Disease, obesity, and Diabetes Type II, Sickle Cell Anemia, Preeclampsia, Sudden Infant Death Syndrome, or Vascular disease comprising positioning ammonia oxidizing bacteria close proximity of a surface of the subject, of nitric oxide and nitric oxide precursors using ammonia oxidizing bacteria. | 2008-09-04 |
| 20080213227 | Mesenchymal stem cells and uses therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 2008-09-04 |
| 20080213228 | Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations - Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells. | 2008-09-04 |
| 20080213229 | Fibrin Contained Semi-Solid Osteoblast Composition for Curing Bone Fracture and Method for Producing the Same - A method for producing the fibrin contained semi-solid osteoblast composition has developed for treating the bone fracture. The method is comprised of: isolating osteoblasts from a bone tissue and culturing/proliferating the isolated osteoblasts in Dulbecco's Modified Eagle's Medium (DMEM) or Minimum Essential Medium, Alpha Modification (α-MEM) to prepare an osteoblast suspension. Then, mixing the resulting osteoblast suspension with a coagulation factor to prepare an osteoblast therapeutic agent. Accordingly, the fibrin contained semi-solid osteoblast composition of the present invention has capability to achieve the bone grafting for performing bone union without the clinical graft rejection. It is possible to uniformly distribute the fibrin mixed semi-solid osteoblast composition into the affected area of the bone fracture via injection. Therefore, the fibrin contained semi-solid osteoblast composition is effectively and rapidly cure the bone fracture via constant injection of into the affected area. | 2008-09-04 |
| 20080213230 | Enriched stem cell and progenitor cell populations, and methods of producing and using such populations - The present invention provides a novel method to isolate and expand pure progenitor/stem cells from a primary tissue explant, which produces a population enriched in multipotent functional progenitor/stem cells free of contaminating fibroblasts and other cell types. Cardiac progenitor/stem cells isolated by this method maintain their self-renewal and clonogenic character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. The present invention also includes substantially pure populations of multipotent progenitor/stem cells, e.g., cardiac progenitor/stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction. | 2008-09-04 |
| 20080213231 | Pluripotent Stem Cell Cloned From Single Cell Derived From Skeletal Muscle Tissue - Techniques are provided which can isolate pluripotent stem cells at high purity capable of differentiation into at least a myocardial cell to regenerate the cardiac muscle. The pluripotent stem cells at high purity capable of differentiation into at least a myocardial cell to regenerate the cardiac muscle can be isolated through the following steps: (i) collecting a skeletal muscle tissue from a mammal and enzymatically treating the obtained skeletal muscle tissue to prepare a skeletal muscle tissue-derived cell; (ii) culturing the obtained skeletal muscle tissue-derived cell in a culture medium containing an epidermal growth factor and a fibroblast growth factor; (iii) selecting and separating a colony that is floating in the culture medium. | 2008-09-04 |
| 20080213232 | Radial Glial Cells Promote Nerve Regeneration and Functional Recovery Following Spinal Cord Injury - An enriched population of radial glial cells has been isolated. These cells are nestin | 2008-09-04 |
| 20080213233 | Method of Delivering Nucleic Acid Molecules Into Embryonic Stem Cells Using Baculoviral Vectors - There is provided a method of delivering a nucleic acid molecule to an embryonic stem cell, including a human embryonic stem cell, by infecting the embryonic stem cell with a baculoviral vector comprising the nucleic acid molecule. Embryonic stem cells transduced by this method are useful for treating a disease or disorder in a subject. | 2008-09-04 |
| 20080213234 | USE OF OSTEOPONTIN FOR THE TREATMENT AND/OR PREVENTION OF NEUROLOGIC DISEASES - The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases. | 2008-09-04 |
| 20080213235 | Adipose Tissue Stem Cells, Perivascular Cells and Pericytes - The present invention provides methods for growing and inducing perivascular cell differentiation of adipose tissue-derived stromal cells. The invention further provides methods for administering such adipose tissue-derived cells to a subject. The cells of the invention are useful for treating diseases, disorders, conditions, and injuries requiring new or enhanced angiogenesis, vascular remodeling, drug delivery, and tissue engineering. | 2008-09-04 |
| 20080213236 | Natural Remedy-Dietary Supplement Combination Product - A natural remedy-dietary supplement combination product which comprises omega-3 fatty acids, α-tocopherol, ascorbic acid, selenium, | 2008-09-04 |
| 20080213237 | Antigen Specific Lymphocytes, Compositions Thereof, and Methods for Isolation and Preparation Thereof - The invention relates to a method for the isolation of T cell lymphocyte, preferably, CD8 | 2008-09-04 |
| 20080213238 | Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair - This invention relates to an improved Lyophilized platelet rich plasma used to make a platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. The improved wound healant comprises therapeutically effective amounts of activated growth factors, platelet ghost, plasma (know as the plasma back bone), white blood cells with optional none, one or more additional anti-oxidant such as vitamin A and/or C and/or E, and/or none one or more antibiotics and/or GHK-Cu (produced by ProCyte Inc.) | 2008-09-04 |
| 20080213239 | FATTY ACID FORMULATIONS AND METHODS OF USE THEREOF - The present invention provides dietary formulations comprising polyunsaturated fatty acids and vitamin E. The present invention further provides methods of treating various conditions, generally involving administering to an individual in need thereof an effective amount of a subject dietary formulation. | 2008-09-04 |
| 20080213240 | RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK - The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor. | 2008-09-04 |
| 20080213241 | PROTEASE COMPOSITION AND METHOD FOR TREATING A DIGESTIVE DISORDER - There is provided methods, kits, combinations, and compositions comprising protease enzymes and a lipase enzyme for treating a digestive disorder in a subject in need thereof. The methods, kits, combinations, and compositions may also be used along with an agent (or combination of agents) for raising the gastric pH, a digestive enzyme useful in enhancing digestive activity, a dietary supplement, or a pharmaceutical agent. | 2008-09-04 |
| 20080213242 | COMPOSITION AND METHOD FOR TREATING PAPILLOMA VIRUS AND EQUINE SARCOIDS - A composition of lysozyme and a pharmaceutically acceptable carrier is active against the papilloma virus in both humans and animals. The composition can be used to treat women suffering from cervical cancer. The composition can also be used to treat cows and horses suffering sarcoids. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR §1.72(b). | 2008-09-04 |
| 20080213243 | Hemostatic materials and dressing - An adhesive material comprising gelatin and a non-toxic cross-linking material such as transglutaminase. The adhesive material is useful for medical purposes as hemostatic products. The hemostatic products are useful for the treatment of wounded tissue. | 2008-09-04 |
| 20080213244 | Glutamate Receptor Antagonists as Neuroprotectives - The invention relates to the use of inhibiting agents of t-PA-mediated activation of the glutamate receptor, for example of the NMDA type, as neuroprotectives. | 2008-09-04 |
| 20080213245 | ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE - Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 2008-09-04 |
| 20080213246 | Supplements For Pain Management - Dietary supplements, compositions and methods of administering the supplements to reduce pain, inflammation and stiffness in said mammal within a few hours. The supplements and compositions can include a combination of an amino acid, vitamins, herbs and enzymes. The composition/supplement can be put in capsule form and when administered to mammals can reduce these symptoms with approximately two hours. reducing the pain and inflammation associated with chronic joint discomfort, chronic low back pain, muscle strain, arthritis, sports injuries, normal everyday bumps and bruises. The novel composition has also been shown to be very effective in reducing monthly menstrual symptoms (PMS). The novel composition can also have benefits for other ailments such as but not limited to Osteoarthritis, Cardiovascular disease, Neurological ailments, Alzheimer disease, and Cancer. | 2008-09-04 |
| 20080213247 | Mbms as Modifiers of Branching Morphogenesis and Methods of Use - Human MBM genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MBM are provided. | 2008-09-04 |
| 20080213248 | Methods and Systems for Treating Asthma and Other Respiratory Diseases - The subject invention provides methods for using TRPM8 receptors as a therapeutic target for identifying effective methods or compounds useful in the diagnosis or treatment of respiratory diseases or conditions. In certain embodiments, compositions that are identified using the methods of the invention are administered to a patient to diagnose or treat a respiratory disease or condition. In a preferred embodiment, TRPM8 receptor blockers are identified and administered, in accordance with the subject invention, to treat a patient with a respiratory disease, such as asthma. | 2008-09-04 |
| 20080213249 | Use of Retro-Aldol Reaction to Generate Reactive Vinyl Ketone for Attachment to Antibody Molecules by Michael Addition Reaction for Use in Immunostaining and Immunotargeting - The present invention is directed to methods for formation of a chemically programmed antibody comprising the steps of: (1) reacting a conjugate comprising a signal module covalently linked to a proadapter with a catalytic moiety selected from the group consisting of a catalytic antibody and a Fab fragment of a catalytic antibody, wherein the proadapter includes therein a precursor to a reactive moiety activated to a reactive moiety by a reaction catalyzed by the catalytic moiety; and (2) crosslinking the reactive moiety to a side chain of an amino acid residue in the active site of the catalytic moiety to produce the chemically programmed antibody. The invention also encompasses chemically programmed antibodies formed by these methods, methods for their use, and pharmaceutical compositions, as well as proadaptors and conjugates including them. Chemically programmed antibodies are useful for the treatment of cancer, particularly in metastasis. | 2008-09-04 |
| 20080213250 | Use of Eph Receptor Inhibitors for the Treatment of Neurodegenerative Diseases - The present invention relates to methods for the screening of gamma secretase modulators, preferably inhibitors as well as to the use of Eph receptor inhibitors for the treatment of neurodegenerative diseases. | 2008-09-04 |
| 20080213251 | HK1-BINDING PROTEINS - The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides. | 2008-09-04 |
| 20080213252 | METHODS OF TREATING ITCH - The invention provides methods for preventing and/or treating itch in a subject in need thereof by administration of a protease-activated G-protein coupled Protease Activated Receptor 4 (PAR4) antagonist. The PAR4 antagonist can be combined with a PAR2 antagonist. | 2008-09-04 |
| 20080213253 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER - Disclosed are new methods for treatment of angiogenesis-related disorders. Angiogenesis-related disorders are treated by administration of a Tie1 ectodomain-binding agent and a vascular disrupting agent. | 2008-09-04 |
| 20080213254 | Bispecific molecules cross-linking ITIM and ITAM for therapy - The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides encoding such bispecific molecules for expression in vivo. One example of an ITAM/ITIM receptor pair is FcεRI and HM | 2008-09-04 |
| 20080213255 | DETERMINING AND REDUCING IMMUNORESISTANCE TO A BOTULINUM TOXIN THERAPY USING BOTULINUM TOXIN B PEPTIDES - The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual. | 2008-09-04 |
| 20080213256 | Less Immunogenic Binding Molecules - The present invention provides a bispecific binding molecule, wherein said molecule comprises or consists of at least two domains whereby one of said at least two domains specifically binds to/interacts with the human CD3 complex and said domain comprises an amino acid sequence of an antibody derived light chain, wherein said amino acid sequence is a particularly identified amino acid sequence comprising specific amino acid substitutions, and a second domain is or contains at least one further antigen-interaction-site and/or at least one further effector domain. The invention further provides nucleic acid molecules encoding the bispecific binding molecules of the invention, vectors comprising said nucleic acid molecules and host cells transformed or transfected with said vectors. Moreover, the invention concerns a method for the production of bispecific binding molecules of the invention and compositions comprising the bispecific binding molecules of the invention, the nucleic acid molecules of the invention or the host cells of the invention. | 2008-09-04 |
| 20080213257 | Methods for treating IL-18 mediated disorders - The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-18 by administering an IL-18 antagonist, such as soluble IL-18 receptor, a soluble IL-18 binding protein and/or an antibody. | 2008-09-04 |
| 20080213258 | Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung - A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. The reference signature defines a standard expression level for each gene and a significant change direction, i.e., either overexpressed or underexpressed. A sample signature that differs from the reference signature in the significant change direction for a predetermined number of the genes tested is indicative of a significant risk of lung metastasis. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations. | 2008-09-04 |
| 20080213259 | Methods for Treating Autoimmune and Chronic Inflammatory Conditions Using Antagonists of CD30 or CD30L - The invention provides methods of treating autoimmnune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors. | 2008-09-04 |
| 20080213260 | USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS - Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL). | 2008-09-04 |
| 20080213261 | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines - The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc. | 2008-09-04 |
| 20080213262 | Inhibition of Islet Amyloid Polypeptide (Iapp) Aggregation for the Treatment of Type 2 Diabetes - The present invention relates to the targeting and clearance of soluable unprocessed Islet Amyloid Polypeptide (hIAPP) in order to prevent the nucleation of hIAPP amyloidogenesis and to interfere with pancreatic cell death which is associated with the aggregation of hIAPP. Agents and methods for reducing hIAPP aggregation are provided herein and may be useful in the treatment of type 2 diabetes. | 2008-09-04 |
| 20080213263 | METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE DYSFUNCTION DISORDERS - Methods and compositions are disclosed for modulating the immune system of animals. Applicants have identified that oral administration of immunoglobulin or plasma fractions purified from animal serum can modulate serum IgG and/or TNF-α levels for treatment of autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans. | 2008-09-04 |
| 20080213264 | COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CHLAMYDIAL INFECTION - Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a | 2008-09-04 |
| 20080213265 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease. | 2008-09-04 |
| 20080213266 | Method for Treating CCR4-Related Diseases - The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition. | 2008-09-04 |
| 20080213267 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 - This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 2008-09-04 |
| 20080213268 | NEUROPILIN ANTAGONISTS - Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications. | 2008-09-04 |
| 20080213269 | Preventive and/or Treating Agent for Cancer - A compound or salt thereof that inhibits the activity of a protein that has an amino acid sequence that is the same or substantially the same as the amino acid sequence shown by SEQ ID NO: 1, a compound or salt thereof that inhibits the expression of the gene for this protein, an antisense polynucleotide that contains a base sequence that is complementary or substantially complementary to the base sequence of a polynucleotide encoding the aforementioned protein or a partial peptide thereof, or that contains a portion of such a base sequence, an antibody against the aforementioned protein, etc., can be used as agents for preventing/treating, for example, cancer, and as agents for promoting cancer cell apoptosis. Protein that has an amino acid sequence that is the same or substantially the same as the amino acid sequence shown by SEQ ID NO: 1, etc., is useful for screening for compounds and salts thereof that act to prevent/treat, for example, cancer. | 2008-09-04 |
| 20080213270 | NEUROTENSIN AS A MARKER AND THERAPEUTIC TARGET FOR SEPSIS - Sepsis is a complex, incompletely understood and often fatal disorder, typically accompanied by hypotension, that is considered to represent a dysregulated host response to an infection. Neurotensin (NT) is 13-amino-acid peptide that, among its multiple effects, induces hypotension. It is shown herein that plasma concentrations of NT are increased in humans with sepsis and in mice after caecal ligation and puncture (CLP), a model of sepsis. Mast cells can degrade NT through neurotensin receptor 1- and neurolysin-dependent mechanisms, diminishing the hypotensive effects of NT, reducing intraperitoneal NT concentrations, and improving survival. These findings show that mast cells can regulate NT concentrations, and identify NT as a biomarker and therapeutic target in sepsis. | 2008-09-04 |
| 20080213271 | Compositions and Methods For Modulating Dopamine Nerutransmission - The present invention provides for diagnosis or treatment of neurological or neuropsyciatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling. | 2008-09-04 |
| 20080213272 | VEGF-RELATED PROTEIN - A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity of VRP, compositions containing the VRP or antibody, methods of use, chimeric polypeptides, and a signal polypeptide for VRP. | 2008-09-04 |
| 20080213273 | Single dose use of CD20-specific binding molecules - The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity using a single dose of CD20-specific binding molecule. | 2008-09-04 |
| 20080213274 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY, AND NEOVASCULARIZATION CONDITIONS OF THE EYE - The present invention relates to compositions and methods for prevention and treatment of ocular diseases and conditions characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of said bioactive lipid. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA). | 2008-09-04 |
| 20080213275 | USE OF MTKI 1 FOR TREATING OR PREVENTING BONE CANCER - The present invention is concerned with the finding that the macrocyclic quinazoline derivative 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclo-pentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication WO2004/105765, is useful in the manufacture of a medicament for the treatment or prevention of bone cancers and methods for killing bone cancer cells, including osteosarcomas, chondrosarcomas, myeloma bone disease and osteolytic bone metastases from other primary sites. It accordingly provides methods for treating, preventing, delaying or mitigating bone cancer, or for preventing and treating of bone loss associated with cancer metastases. | 2008-09-04 |
| 20080213276 | Modulation of neural stem cells and neural progenitor cells - The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells via S1P or LPA signaling. These methods are useful for reducing at least one symptom of the disorder. | 2008-09-04 |
| 20080213277 | HEPCIDIN, HEPCIDIN ANTAGONISTS AND METHODS OF USE - The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders. | 2008-09-04 |
| 20080213278 | Method Of Treating Disorders Using Compositions Comprising Zotarolimus And Paclitaxel - A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs. | 2008-09-04 |
| 20080213279 | Blocking Leukocyte Emigration and Inflammation By Interfering With Cd99l2 - The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to treating inflammatory conditions. The invention specifically relates to the discovery that the adhesion molecule CD99L2 mediates TEM of leukocytes. CD99L2 is present on endothelial cells and leukocytes and mediates leukocyte-endothelial cell adhesion. Blockade of CD99L2 by use of a specific antibody blocks migration of leukocytes into a site of inflammation. CD99L2 shows functional analogy to the structurally-related molecule, CD99, inhibition of which, in conjunction with inhibition of PECAM, causes near total blockade of TEM. Thus, blocking CD99L2 on either endothelial cells or monocytes can block migration 80-90%. In conjunction with PECAM inhibitors, TEM blockade can approach 100%. Therapeutic treatments involving inhibition of CD99L2 show significant promise in remediation of inflammatory conditions. | 2008-09-04 |
| 20080213280 | THERAPY OF AUTOIMMUNE DISEASE IN A PATIENT WITH AN INADEQUATE RESPONSE TO A TNF-ALPHA INHIBITOR - The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor. | 2008-09-04 |
| 20080213281 | Butyrylcholinesterase Variants that Alter the Activity of Chemotherapeutic Agents - The invention provides a butyrylchinesterase variant, a method of converting a camptothecin derivative to a topoisomerase inhibitor by contacting the camptothecin derivative with a butyrylcholinesterase variant and a method of treating cancer by administering to an individual an effective amount a butyrylcholinesterase variant exhibiting increased capability to convert a camptothecin derivative to a topoisomerase inhibitor compared to butyrylcholinesterase. | 2008-09-04 |
| 20080213282 | Formulations - The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the formulation. | 2008-09-04 |
| 20080213283 | USE OF CERTAIN DRUGS FOR TREATING NERVE ROOT INJURY - The present invention relates to a method for treating nerve disorders in a mammal or a vertebrate by administering a TNF-alpha inhibitor. The invention also relates to the use of a TNF-alpha inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury and other nerve disorder. | 2008-09-04 |
| 20080213284 | RECEPTOR BINDING POLYPEPTIDES - Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed. | 2008-09-04 |
| 20080213285 | SECRETED CHLAMYDIA POLYPEPTIDES, POLYNUCLEOTIDES CODING THEREFOR, THERAPEUTIC AND DIAGNOSTIC USES THEREOF - The present invention relates to secreted | 2008-09-04 |
| 20080213286 | Mam Domain Containing Protein - This invention relates to a novel protein, termed INSP152, herein identified as a secreted protein, in particular, as a MAM domain containing protein and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment. | 2008-09-04 |
| 20080213287 | Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell - A method of inhibiting infection by Flaviviridae viruses including HCV, GBC/HGV, and BVD in addition to VSV and any other virus capable of forming a complex with a lipoprotein strategies: preventing formation of a complex should one form, altering the conformation of such a complex to prevent its interaction with the cell receptor, blocking the cell receptor for the complex using an antibody to the receptor, blocking binding of the lipoprotein complex to the cell receptor using soluble lipoprotein receptor or fragments thereof, or downregulating the LDL receptor activity of the cells. | 2008-09-04 |
| 20080213288 | Combined Use Of A Modulator Of CD3 And A GLP-1 Compound - Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound. | 2008-09-04 |
| 20080213289 | RECOMBINANT ANTI-CD30 ANTIBODIES AND USES THEREOF - The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease. | 2008-09-04 |
| 20080213290 | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene - Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection. | 2008-09-04 |
| 20080213291 | Malaria vaccines - The invention provides isolated placental | 2008-09-04 |
| 20080213292 | Soluble And Stabilized Trimeric Form Of Gp41 Polypeptides - The present invention concerns a modified polypeptide containing at least an immunodominant region and the connecting loop between N- and C-helices of gp41 ectodomain of HIV-1, wherein the connecting loop includes at least a linker fragment having: —a size convenient for keeping the native conformation of the interaction between N- and C-helices, and—an hydrophily sufficient to provide a soluble and stable trimeric form to said modified polypeptide. | 2008-09-04 |
| 20080213293 | Prevention and Treatment of Recurrent Respiratory Papillomatosis - Juvenile-onset recurrent respiratory papillomatosis is treated using active vaccination or passive immune therapy of neutralizing antibodies against HPV L2 neutralizing epitopes. | 2008-09-04 |
| 20080213294 | Immunization of dairy cattle with GapC protein against streptococcus infection - The GapC plasmin binding protein genes of | 2008-09-04 |
| 20080213295 | HER-2/NEU FUSION PROTEINS - The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene. | 2008-09-04 |
| 20080213296 | Immunogen - The present invention relates, in general, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same. | 2008-09-04 |
| 20080213297 | Method of producing conjugate vaccines - The present invention relates to a method of production of a hydrazide modified sugar comprising a step of reacting a sugar with a hydrazide in a reaction solvent at a pH of between 3 and 5.5, wherein the solvent comprises an aqueous based solvent and an optional polar organic co-solvent. A further aspect of the invention relates to a method of production of a polysaccharide epitope carrier protein conjugate comprising the steps of: (a) reacting a polysaccharide epitope with a hydrazide to form a hydrazide modified polysaccharide epitope; (b) reacting the hydrazide modified polysaccharide epitope with a linker that has been pre-coupled to a carrier protein. Another aspect of the invention relates to a method of production of a sugar-dihydrazide-aldehyde adduct comprising the steps of: (a) producing a hydrazide modified sugar using a method according to the invention, wherein the hydrazide modified sugar includes a further unreacted hydrazide moiety; and (b) reacting the further hydrazide moiety with the aldehyde functionality of a linker group. | 2008-09-04 |
| 20080213298 | Herbal Therapy for the Treatment of Asthma - The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of asthma and asthma-related symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of asthmatic symptoms in a patient in need thereof. | 2008-09-04 |
| 20080213299 | Silver-Ionized Plant Extraction Liquid and Use Thereof - The present invention relates to a silver-ionized plant extraction liquid and the use thereof. Particularly, there are provided herein a silver-ionized liquid extraction liquid prepared by ionizing silver in a plant extraction liquid used as an electrolyte and an antimicrobial composition comprising the same. | 2008-09-04 |
| 20080213300 | Compositions for Juice-Based Treatment Serums - The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials. | 2008-09-04 |
| 20080213301 | COMPOSITIONS AND METHODS FOR HEALTHY PREGNANCY - Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of an embryo. | 2008-09-04 |
| 20080213302 | Methods for treating cancer with MVA - The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus. | 2008-09-04 |
| 20080213303 | MUTANT FORMS OF CHOLERA HOLOTOXIN AS AN ADJUVANT - Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule. | 2008-09-04 |
| 20080213304 | Methods of Treating and Preventing Neurological Symptons Caused by Avian Reovirus and Novel Associated Characteristics - Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise and immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms. | 2008-09-04 |
| 20080213305 | Vaccine for periodontitis and methods of use - The present invention is directed to an immunogenic composition for inducing an immune response against lysine decarboxylase for treating or preventing periodontitis in a subject. The present invention is also directed to methods for inducing an immunogenic response in a subject by administering such immunogenic composition. | 2008-09-04 |
| 20080213306 | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines - The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE. | 2008-09-04 |
| 20080213307 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 2008-09-04 |
| 20080213308 | Imidazoquinoline Compounds - The invention provides novel compositions comprising imidazoquinoline compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s). | 2008-09-04 |
| 20080213309 | MULTI-ANTIGENIC ALPHAVIRUS REPLICON PARTICLES AND METHODS - Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector. | 2008-09-04 |
| 20080213310 | Use of lytic toxins and toxin conjugates - Agents are provided which are capable of inhibiting the cell division cycle in a target cell of interest. The agents comprise first and second components, wherein the first component is a targeting moiety which is capable of directing the second component to the target cell of interest. The second component is capable of inhibiting the cell division cycle in the target cell of interest. The agents are preferably provided in the form of conjugates, and the second component is preferably a cytolethal distending toxin. Methods for the preparation of the agents, and the use thereof for treating proliferative cell disorders and intracellular pathogens are also provided. | 2008-09-04 |
| 20080213311 | CLOSTRIDIAL TOXIN DERIVATIVES AND METHODS FOR TREATING PAIN - Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds. | 2008-09-04 |
| 20080213312 | BOTULINUM TOXIN TREATMENTS - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 2008-09-04 |
| 20080213313 | BOTULINUM TOXIN TREATMENTS - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 2008-09-04 |
| 20080213314 | COMBINED DNA VACCINE AND BIOLOGICAL MODIFIERS FOR CANCER THERAPY - The present invention relates to the combination of a DNA vaccination strategy that makes use of a nucleic acid encoding an immunogenic polypeptide, with a non-immunosuppressive inducer of tumor cell differentiation and/or apoptosis or a tumor cell modifier, useful for cancer therapy. Vaccine compositions and kits are provided, as well as specific nucleic acid constructs that are particularly suitable for the preparation of such compositions. | 2008-09-04 |
| 20080213315 | CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS - A botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising a botulinum toxin and a recombinant albumin, suitable for therapeutic administration to a human patient, and methods for treating patients with various diseases and afflictions with the formulation. | 2008-09-04 |
